Acute tumour lysis syndrome: A case in AL amyloidosis

British Journal of Haematology

Volumn 107, Issue 2, 1999, Pages 386-387

  Akasheh, Marwan S ^a,b   Ciiang, P ^a,b   Vesole, David H ^a,b  

^a FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Amyloidosis; ASCT; Melphalan; Multiple myeloma; Tumour lysis syndrome

Indexed keywords

ALLOPURINOL; DEXAMETHASONE; MELPHALAN; PREDNISONE; ALKYLATING AGENT;

AGED; AMYLOIDOSIS; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; DRUG INDUCED DISEASE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOPROLIFERATIVE DISEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; ACUTE DISEASE; FATALITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; TUMOR LYSIS SYNDROME;

ACUTE DISEASE; AGED; AMYLOIDOSIS; ANTINEOPLASTIC AGENTS, ALKYLATING; FATAL OUTCOME; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MELPHALAN; TUMOR LYSIS SYNDROME;

EID: 0032708634     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01719.x     Document Type: Article

References (10)

1. Burton, D. & Robert, M.B. (1988) Manual of Clinical Problems in Nephrology, Chap. 48. pp. 304-308. Little. Brown and Co., Boston.
2. Comenzo. R.. Vosburgh, E., Falk. R., Sanchorawala. V., Reisinger, J., Dubrey, S., Dcmber, L., Berk, J., Akpek, G., La Valley, M., O'Hara, C., Arkin, C., Wright, D. & Skinner, M. (1998) Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood, 91, 3662-3670.
3. Passas. A., Desikan, K.R., Copier. T., Siegel, D., Mehta, J., Mattox, S.. Jagnnath, S.. Tricot, G. & Barlogie, B. (1997) Tumor lysis syndrome following intermediate and high dose therapy in patients with multiple myeloma: association with high tumor mass, immature morphology, high labeling index and abnormal cytogenetics. Blood. 90, (Suppl. 1), 527a. abs. 2347.
4. Kyle, R. & Bayrd. E. (1975) Amyloidosis: review of 236 cases. Medicine (Baltimore). 54, 271-299.
5. Kyle. A.. Gertz. M., Greipp, P., Witzig. T., Lust, J., Lacy, M. & Therneau, T. (1997) A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prcdnisone, and melphalan, prednisone, and colchicine. New England Journal of Medicine. 336, 1202-1207.
6. Kyle. R., Greipp, P. & O'Fallon, W. (1986) Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood. 68, 220-224.
7. Merlini. G. (1995) Treatment of primary amyloidosis. Seminars in Ikmatology. 32/60-79.
8. Moreau, P., Leblond, V., Bourquelot, P., Façon, T., Hunh, A., Caillot, D., Hermine, 0.. Altai, M., Hamidou, M.. Nedellec. G.. Ferrant, A.. Audhuy, B.. Bataille, R., Milpied. N. & Harousseau, J.L. (1998) Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. British Journal of Haematoloay. 101, 766-769.
9. Nakhoul, F., Green, J., Abassi. Z. & Carter, A. (1996) Tumour lysis syndrome induced by fludarabine monophosphate: a case report. European Journal of Haematology, 56, 254-255.
10. Van Buren. M., Hene, R., Verdonck, L., Verzijilbergen. F. & Lokhorst, H. (1995) Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis. Annals of Internal Medicine. 122, 508-510.